Ribupatide for Weight Loss: Oral and Injectable GLP-1/GIP Results

Ribupatide is an investigational dual GLP-1/GIP receptor agonist being developed in both once-weekly injectable and once-daily oral forms for obesity and overweight. The injectable version is further along in global Phase 3 development, while oral ribupatide has early Phase 2 data from China.

The strongest injectable data reported so far include up to 19.2% mean weight loss at 48 weeks in a Phase 3 China trial and up to 23.6% mean weight loss at 36 weeks in a separate higher-dose Phase 2 analysis. Oral ribupatide showed up to 12.1% mean weight loss at 26 weeks in a Phase 2 trial.

This article focuses on ribupatide results, side effects, dosing studied in trials, and current development status. It does not provide dosing instructions or support gray-market peptide use.

Who this is for: Readers tracking oral and injectable ribupatide trial results, GLP-1/GIP drug development, and emerging weight-loss medications.

Who this is not for: Anyone trying to buy, compound, inject, or self-dose ribupatide outside a regulated clinical trial.

Reviewed by VerifiedSupps Editorial Team • Last reviewed: June 1, 2026

Does ribupatide work for weight loss?

Early and mid-to-late-stage data suggest ribupatide can produce clinically meaningful weight loss, especially as a weekly injection. The oral version also has promising Phase 2 data, but it is earlier and needs more confirmation.

Ribupatide, also called KAI-9531 by Kailera and HRS9531 by Hengrui in Greater China, targets both GLP-1 and GIP receptors. That puts it in the same broad dual-incretin category as tirzepatide and CT-388, though cross-drug comparisons should be made carefully.

The key point is that ribupatide’s biology is plausible, and the weight-loss results are notable, but it still needs large global data before it can be judged like an approved medication. For a related mechanism discussion, see how retatrutide works and retatrutide vs tirzepatide.

What were the injectable ribupatide weight-loss results?

Injectable ribupatide has produced the strongest results so far, including up to 19.2% mean weight loss at 48 weeks in a Phase 3 China trial and up to 23.6% at 36 weeks in a separate higher-dose Phase 2 analysis. These are strong signals, but they are not yet the same as completed U.S. or global approval data.

The injectable program is important because it is the version now being tested in Kailera’s global Phase 3 KaiNETIC trials.

The Phase 3 China result is useful because it tested ribupatide in a larger late-stage setting. The 8 mg Phase 2 result is also important because it suggests higher doses may produce larger weight loss, which is why Kailera is studying doses up to 10 mg in Phase 3 and up to 20 mg in a separate Phase 2b high-dose trial.

A cautious reader should avoid one common mistake: do not compare ribupatide’s 36-week, 48-week, and future 76-week results as if they came from the same study design. Dose, duration, population, estimand, and trial conduct all matter.

What were the oral ribupatide weight-loss results?

Oral ribupatide showed up to 12.1% mean weight loss at 26 weeks in a Phase 2 China trial. That is notable for an oral GLP-1/GIP peptide candidate, but it is still early compared with the injectable program.

The oral version is also known as HRS9531 tablet or KAI-9531-T. It is being developed as a once-daily tablet, while injectable ribupatide is being developed as a once-weekly shot.

The treatment-policy estimand showed similar but slightly different results: 6.7% at 10 mg, 11.9% at 25 mg, and 11.4% at 50 mg, compared with 2.1% for placebo. That matters because estimands answer different trial questions, especially when discontinuation or nonadherence occurs.

Oral ribupatide should also be separated from other oral weight-loss candidates. For example, oral VK2735 is another dual GLP-1/GIP candidate, while oral GLP-1-only drugs follow a different approach. The oral obesity-drug space is promising, but still highly competitive and fast-moving.

What ribupatide dose was used in trials?

Ribupatide has no approved dose. Trial doses include once-weekly injectable doses studied at 2, 4, 6, 8, and higher planned doses, while oral ribupatide has been studied as once-daily 10, 25, and 50 mg tablets.

These are research doses, not consumer instructions. Dose escalation and medical monitoring are central to the clinical trial design.

• Injectable ribupatide: Studied as a once-weekly subcutaneous injection.
• China Phase 3 injection: Tested 2 mg, 4 mg, and 6 mg over 48 weeks.
• Higher-dose injectable data: An 8 mg dose showed larger 36-week weight loss in Phase 2.
• Global Phase 3 KaiNETIC: Designed to evaluate weekly doses up to 10 mg over 76 weeks.
• High-dose Phase 2b: Designed to evaluate injectable doses up to 20 mg over 48 weeks.
• Oral ribupatide: Studied as once-daily 10 mg, 25 mg, and 50 mg tablets in Phase 2.

The oral Phase 2 study used a simple titration schedule, reaching 10 mg and 25 mg by week 4 and 50 mg by week 8. That does not mean those doses are appropriate outside a trial; it only describes how the study was conducted.

If you are seeing ribupatide vials, tablets, or “research use only” products online, treat that as a major safety red flag. For the bigger framework, read Are Peptides Safe?.

What are the side effects of ribupatide?

The main ribupatide side effects reported so far are gastrointestinal, broadly consistent with GLP-1-based obesity drugs. Nausea, vomiting, diarrhea, constipation, decreased appetite, and abdominal symptoms are the key issues to watch.

So far, sponsor-reported trial summaries have described most adverse events as mild to moderate. That is encouraging, but full peer-reviewed data and larger global datasets are still needed before the safety profile is clear.

Large weight loss can also include lean mass loss if nutrition and resistance training are not managed. That issue is not unique to ribupatide. For more context, see our guides on muscle loss with incretin-based weight loss and how much protein you actually need.

Is ribupatide approved or available yet?

No. Ribupatide is not FDA-approved and is not available as a normal prescription weight-loss medicine in the United States. Current legitimate access should be limited to regulated clinical trials.

The current status depends on the region and formulation. Hengrui has advanced HRS9531 in China, while Kailera is developing ribupatide outside Greater China.

• Injectable ribupatide outside Greater China: Global Phase 3 KaiNETIC program is underway.
• Injectable HRS9531 in China: Hengrui submitted a marketing authorization application to China’s NMPA for long-term weight management in adults.
• Oral ribupatide in China: Hengrui plans to advance oral ribupatide into Phase 3 for obesity.
• Oral ribupatide globally: Kailera plans to initiate a global Phase 2 trial.
• Global injectable data timing: Kailera has indicated KaiNETIC topline results are anticipated in 2028, while a high-dose Phase 2b trial is expected to report topline results in 2027.

A realistic U.S. timeline cannot be stated yet. FDA approval would require successful global trials, a regulatory submission, FDA review, manufacturing review, labeling decisions, and post-approval launch planning.

The conservative takeaway: ribupatide is one to watch, not one to use. Products marketed online as ribupatide, HRS9531, KAI-9531, or “research GLP-1/GIP” should not be treated as safe, verified, or legitimate for personal use.

How does ribupatide compare with other GLP-1/GIP weight-loss drugs?

Ribupatide belongs in the same broad dual-incretin conversation as tirzepatide, CT-388, and VK2735, but it is not approved and should not be ranked from headline percentages alone. The most useful comparison is by evidence maturity, route, and trial duration.

Compared with approved drugs, ribupatide has less regulatory certainty. Compared with pipeline drugs, its injectable data are relatively advanced, and its oral data are interesting but earlier.

For other pipeline strategies, see CagriSema for weight loss, petrelintide for weight loss, amycretin for weight loss, and pemvidutide for weight loss and fatty liver. These drugs use different receptor strategies, so direct comparisons need caution.